Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

NCT03993353 is registered in ClinicalTrials.gov with University of California, San Diego as lead sponsor.

NCT NCT03993353
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03993353 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Lead sponsor
University of California, San Diego
Phase
Phase 2
Overall status
Completed
Start date
April 7, 2020
Completion date
January 9, 2024
Enrollment
7 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, cancer of esophagus, cancer of head and neck, cancer of mouth, cancer of neck, cancer, metastatic, head and neck cancer, head and neck cancer metastatic, head and neck cancer stage iii, head and neck cancer stage iv, head and neck carcinoma, head and neck squamous cell carcinoma